|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Santarus, Inc. - SWOT Analysis |
|
|
|
|
€ 100,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Avril 2008 |
Taille du document : |
23 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Pharmacogenomics Outlook
174 pages | Août 2000 |
Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development.
By identifying differenc |
955,00 €
|
| |
| |
ePharmacies: Strategic Implications for the Healthcare Industry
230 pages | Mars 2000 |
Increasingly, the pharmaceutical sector is being influenced by the Internet.Are you in a position to:- Predict future shifts in drug prescribing and purchasing behavior?- Anticipate consolidation in b |
955,00 €
|
| |
| |
Antisense Therapy: Technical Aspects and Commercial Opportunities
334 pages | Mars 2000 |
Antisense therapy interferes with the expression of disease-causing proteins, thus offering a direct and selective intervention in the disease process.
Besides the well known oligonucleotides ( |
955,00 €
|
| |
| |
The Global Parallel Trade Outlook 2001 - 2006: A Country-by-Country Analysis
188 pages | Septembre 2001 |
Global Parallel Trade Outlook 2001: A country-by-country analysis, a new report by Reuters Business Insight, provides a detailed update on the status of parallel trade in the global marketplace.
1 200,00 €
|
|
| |
| |
Pharmaceutical Mergers & Aquisitions: the third wave
160 pages | Février 1999 |
Historical assessment : The report identifies the factors that have driven the two historical waves of M&A activity, and analyses the relative importance of these factors through case studies.
795,00 €
|
|
| |
| |
European Pharmaceutical Industry
35 pages | Juillet 2002 |
The Pharmaceutical industry remains one of Europe’s best performing sectors (employment, R&D and trade surplus).
The world pharmaceutical market was worth an estimated € 392,640 million (at ex-fact |
600,00 €
|
| |
| |
The UK piling Market
40 pages | Mai 2002 |
This report will enable you to:Analyse the size of the UK market for piling between 1997 and 2006Quantify the size of the UK market for piling, 1997-2006, by technique: - bored - driven - embedded |
365,00 €
|
| |
| |
Chinese Markets for OTC Drugs
220 pages | Février 2002 |
China's demand for OTC drugs has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic trend |
3 500,00 €
|
| |
| |
Top Ten and Emerging Pharmaceutical markets
214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals.
Mar |
795,00 €
|
| |
| |
The Japanese Pharmaceutical Market Outlook 2001
142 pages | Août 2001 |
Although Japan is the second largest pharmaceutical market in the world, it has traditionally been a relative 'no-go' area for pre-eminent Western drug companies.
Now, however, extensive cultur |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Santarus, Inc. - SWOT Analysis |
|
|
Datamonitor's Santarus, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Santarus is a specialty pharmaceutical company focused on acquiring, developing and commercializing products for patients with gastrointestinal diseases and disorders. The company is headquartered in San Diego, California and employs 338 people as of December 2006. *The company recorded revenues of $94.4 million during the fiscal year ended December 2007, an increase of 91.8% over 2006. The operating loss of the company was $47.3 million during fiscal year 2007, as compared to an operating loss of $59.5 million in 2006. The net loss was $44.3 million in fiscal year 2007, as compared to the net loss of $56.5 million in 2006. *Unaudited results http://phx.corporate-ir.net/phoenix.zhtml?c=175502&p=irol-newsArticle&ID=1114779&highlight=
Scope of the Report
- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement
Reasons to Purchase
- Support sales activities by understanding your customers’ businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors’ business structure, strategy and prospects
- Obtain the most up to date company information available
|
|
Table of Contents:
This product typically includes the following sections:
Key Facts
Company Overview
Business Description
Company History
Key Employees
Key Employee Biographies
Company View
SWOT analysis
Products & Services Listing
Products & Services Analysis
|
|
|
PPLSEN
|
|
|
|
|
